U.S., April 7 -- ClinicalTrials.gov registry received information related to the study (NCT07510802) titled 'Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC' on March 20.
Brief Summary: This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1,TNBC cases mesothelin), each participant will receive the most suitable dual-target CAR-NK product for their tumor profile, following short-course lymphodepleting chemotherapy.
Study Start Date: Feb. 02
Study Type: INTERVENTIONAL
Condition:
Breast Cancer (Advanced/Metastatic)
HER2-posit...